Abstract
The morbidity of myocarditis demonstrates an upward tendency by years, is commonly defined as the inflammation of myocytes and is caused by multiple factors. With the development of the molecular biological technique, great breakthroughs in the diagnosis and understanding of pathophysiological mechanisms of myocarditis have recently been achieved. Several questions remain unresolved, however, including standard treatment approaches to myocarditis, which remain controversial and ambiguous. Heart rate, as an independent risk factor, has been shown to be related to cardiac disease. Recent studies also show that the autonomic nervous system is involved in immunomodulatory myocarditis processes. Heart rate reduction treatment is recommended in myocarditis based on a number of animal experiments and clinical trials. It is possible that heart rate-lowering treatments can help to attenuate the inflammatory response and myocyte injury and reverse ventricular remodeling. However, how to execute the protective effects of heart rate reduction on myocarditis is still not clear. In this review, we discuss the pathogenesis and pathophysiological process of viral myocarditis and propose heart rate lowering as a therapeutic target for myocarditis, especially in light of the third-generation β-blockade carvedilol and funny channel blocker ivabradine. We also highlight some additional beneficial effects of such heart rate reduction agents, including anti-inflammatory, antioxidation, anti-nitrosative stress, anti-fibrosis and antiapoptosis properties.
Keywords: Heart rate, myocarditis, autonomic nervous system, carvedilol, ivabradine, anti-inflammatory.
Current Pharmaceutical Design
Title:Role of Heart Rate Reduction in the Management of Myocarditis
Volume: 24 Issue: 3
Author(s): Chen Guang-Yi, Ge Li-Sha and Li Yue-Chun*
Affiliation:
- Department of Cardiology, Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000,China
Keywords: Heart rate, myocarditis, autonomic nervous system, carvedilol, ivabradine, anti-inflammatory.
Abstract: The morbidity of myocarditis demonstrates an upward tendency by years, is commonly defined as the inflammation of myocytes and is caused by multiple factors. With the development of the molecular biological technique, great breakthroughs in the diagnosis and understanding of pathophysiological mechanisms of myocarditis have recently been achieved. Several questions remain unresolved, however, including standard treatment approaches to myocarditis, which remain controversial and ambiguous. Heart rate, as an independent risk factor, has been shown to be related to cardiac disease. Recent studies also show that the autonomic nervous system is involved in immunomodulatory myocarditis processes. Heart rate reduction treatment is recommended in myocarditis based on a number of animal experiments and clinical trials. It is possible that heart rate-lowering treatments can help to attenuate the inflammatory response and myocyte injury and reverse ventricular remodeling. However, how to execute the protective effects of heart rate reduction on myocarditis is still not clear. In this review, we discuss the pathogenesis and pathophysiological process of viral myocarditis and propose heart rate lowering as a therapeutic target for myocarditis, especially in light of the third-generation β-blockade carvedilol and funny channel blocker ivabradine. We also highlight some additional beneficial effects of such heart rate reduction agents, including anti-inflammatory, antioxidation, anti-nitrosative stress, anti-fibrosis and antiapoptosis properties.
Export Options
About this article
Cite this article as:
Guang-Yi Chen , Li-Sha Ge and Yue-Chun Li *, Role of Heart Rate Reduction in the Management of Myocarditis, Current Pharmaceutical Design 2018; 24 (3) . https://dx.doi.org/10.2174/1381612824666180111105923
DOI https://dx.doi.org/10.2174/1381612824666180111105923 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Ryanodine Receptor Patents
Recent Patents on Biotechnology Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Recent Patents on Stimuli Responsive Hydrogel Drug Delivery System
Recent Patents on Drug Delivery & Formulation Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Editorial (Thematic Issue: Cardiovascular Drug Therapy in Paediatric Age: From Metabolomics to Clinical Practice)
Current Medicinal Chemistry A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science